Pharma business info

Swiss pharma giant Novartis stated that it is purchasing dermatology generics firm Fougera for around $1.525 billion, a move that would propel the group to market head spot on generic dermatology medications.

Watson Pharmaceuticals first-quarter income surged 22% as the drug manufacturer announced sharply higher income with a boost from novel generic medications and as its branded pharmaceuticals and distribution biz also registered double-digit growth.

Endo Pharmaceuticals posted a first-quarter loss after assimilating a $110-million pre-tax charge linked to a settlement and license agreement with Impax Laboratories Inc.

Watson Pharmaceuticals has purchased Actavis for approximately $5.6 billion, paying $1 billion less for the Swiss generic drug manufacturer than initial M&A hearsays had hinted.

Pfizer Inc., the globe’s largest drug manufacturer, and Mylan Inc. stated that they settled patent-infringement lawsuit with Teva Pharmaceutical Industries Ltd. over a device utilized to insert epinephrine during potentially fatal allergies.

Drugmaker Jazz Pharmaceuticals PLC stated that it will get hold of cancer drug manufacturer EUSA Pharma Inc. in a transaction worth around $700 million.

Shares of diabetes drug manufacturer Amylin Pharmaceuticals Inc. soared on April 23 accompanying a report the firm is reaching out to prospective buyers on a possible sale.

Sun Pharmaceutical Industries Ltd. has announced that USFDA has given nod for its Abbreviated New Drug Application for generic edition of Zyprexa, Olanzapine tabs USP, 2.5mg, 5mg, 7.5mg,10mg, 15mg and 20mg

Pfizer Pfizer is determined on throwing away noncore biz groups. AstraZeneca is intent on appending any small firm, which might bring returns.

Novartis AG's (NVS) head of pharmaceuticals David Epstein stated that Gilenya will be a smash hit in spite of the improbability surrounding the multiple sclerosis tablet's safety.

SXC Health Solutions Corp stated that will purchase rival pharmacy benefit manager Catalyst Health Solutions Inc for $4.4 billion as it tries to keep pace in the speedily consolidating market for managing Americans' prescriptions.

Research-based pharmaceutical and healthcare firm Glaxosmithkline stated that it has reached deal to sell the previously recognized non-core OTC brands in its global markets to Aspen Pharmacare Holdings Ltd. for GBP164 million in cash.

Sherilyn McCoy, a vice chairman of the Johnson & Johnson executive board, resigned to take the top post at cosmetics company Avon.

Avon Products, the cosmetics firm that has been under pressure amid a regulatory probe and slumping sales, has appointed a new leader.

Recently, Allos Therapeutics, and Spectrum Pharmaceuticals entered into a deal through which the latter decided to get hold of the former for $1.82 a share in cash, besides one contingent value right (CVR).

Optimer Pharmaceuticals Inc. (OPTR) has shaken up its control, mentioning lapses in corporate governance practices and the drug manufacturer's connection with a Taiwanese associate.

The Swiss pharmaceutical firm Roche Holding AG has decided to offer sharply discounted editions of two cancer medications in the Indian market.

Patients will expire because of the administration's reforms to the NHS, the editor of a respected medical journal claimed yesterday.
‎
Teva Pharmaceutical Industries, the globe's largest generic drug manufacturer, plans to offer senior notes denominated in euros and Swiss francs outside the US.

Watson Pharmaceuticals soared during noon trading on Wednesday after an anonymously sourced report stated that it is near to buying Swiss counterpart Actavis.

Dainippon Sumitomo Pharma Co. declared its plans to buy U.S. biotechnology business enterprise Boston Biomedical Inc. for $200 million, with milestone payments potentially bringing the transaction to around 2.63 billion dollars.

Sun Pharmaceutical Industries stated that it has bagged nod from the US health watchdog for its generic Zyprexa Zydis pills, utiized in handling psychological disorder, in the US market.

AstaraZeneca Pharma India stated that it is undertaking voluntary recall of sterile products fabricated at its Bangalore plant.

Hyderabad based pharmaceutical maker Cheminnova has inked a JV deal with Brisbane-based neutraceuticals company Rapid Nutrition Ltd.

Aashish Tater, Head of Research, Fort Share Broking stated that the stock of AstraZeneca Pharma can be purchased to attain a target of Rs 2250-2500.

Salix Pharmaceuticals Ltd. has recorded fourth quarter net income of $33.6 million ($0.56 per share) as against $24.5 million or $0.40 per share during the same period of last year.

Raging Capital Management, LLC ("Raging Capital"), one of the largest unaffiliated shareholders of Taro Pharma declared that it forwarded a letter to the company’s board asking for that it instantly disallow the October 18, 2011 offer of Sun Pharmaceutical Industries Ltd. to get hold of all of the resting outstanding shares of Taro.

Aventis Pharma has registered a net profit of Rs 361 million for the three month period ended December 31, 2011 as against Rs 1,049 million during the same period of 2010, representing diminution of 65.59%.

Auxilium Pharmaceuticals, a specialty biopharmaceutical firm, and Basel, Switzerland-based biopharmaceutical firm, Actelion Pharmaceuticals Ltd. have inked a long-term partnership agreement for the growth, supply and sale of Xiaflex

Satori Pharmaceuticals has put down $15.5 million in funding to further its study in the cure of Alzheimer’s illness, the company made this declaration.

Johnson & Johnson has named Alex Gorsky as its new chief executive officer. Alex will succeed William Weldon

Aurobindo Pharma Ltd’s scrip dropped 5.67% on the Bombay Stock Exchange (BSE) on February 10 following reports of IT raids and sudden annulment of board conference.

Cambridge based Ironwood Pharmaceuticals has declared that it is offering up 5.3 million Class A scrips to aid toughen its balance sheet.

The ex biz development director of Takeda Pharmaceuticals International made $63,000 in profits from insider trading.

Sun Pharmaceuticals, India’s biggest drug manufacturer by market cap, is ready to declare its outcomes for the three month period ended December FY12 on February 13.